<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vavilov</journal-id><journal-title-group><journal-title xml:lang="ru">Вавиловский журнал генетики и селекции</journal-title><trans-title-group xml:lang="en"><trans-title>Vavilov Journal of Genetics and Breeding</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2500-3259</issn><publisher><publisher-name>Institute of Cytology and Genetics of Siberian Branch of the RAS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18699/VJ16.207</article-id><article-id custom-type="elpub" pub-id-type="custom">vavilov-876</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Актуальные технологии генетики и клеточной биологии</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Mainstream technologies in genetics and cell biology</subject></subj-group></article-categories><title-group><article-title>Cравнительное изучение репликативных свойств противоопухолевых рекомбинантных вирусов осповакцины на культурах клеток глиобластомы человека U87 и почки мартышки CV-1</article-title><trans-title-group xml:lang="en"><trans-title>A comparative study of replicative properties of antitumor recombinant vaccinia viruses on human glioblastoma cell culture U87 and monkey kidney cell culture CV-1</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максютов</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksyutov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кольцово, Новосибирская область, Россия</p></bio><bio xml:lang="en"><p>Koltsovo, Novosibirsk region, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колосова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolosova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кольцово, Новосибирская область, Россия</p></bio><bio xml:lang="en"><p>Koltsovo, Novosibirsk region, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трегубчак</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tregubchak</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кольцово, Новосибирская область, Россия</p></bio><bio xml:lang="en"><p>Koltsovo, Novosibirsk region, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Разумов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Razumov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новосибирск, Россия</p></bio><bio xml:lang="en"><p>Novosibirsk region, Russia</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щелкунов</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchelkunov</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кольцово, Новосибирская область, Россия</p></bio><bio xml:lang="en"><p>Koltsovo, Novosibirsk region, Russia</p></bio><email xlink:type="simple">snshchel@vector.nsc.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии «Вектор»<country>Россия</country></aff><aff xml:lang="en">State Research Center of Virology and Biotechnology ”Vector”,<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии «Вектор»<country>Россия</country></aff><aff xml:lang="en">State Research Center of Virology and Biotechnology ”Vector”<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Федеральное государственное бюджетное научное учреждение «Федеральный исследовательский центр Институт цитологии и генетики&#13;
Сибирского отделения Российской академии наук»<country>Россия</country></aff><aff xml:lang="en">Institute of Cytology and Genetics SB RAS<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">Федеральное бюджетное учреждение науки Государственный научный центр вирусологии и биотехнологии «Вектор»&#13;
&#13;
Федеральное государственное бюджетное научное учреждение «Федеральный исследовательский центр Институт цитологии и генетики&#13;
Сибирского отделения Российской академии наук»<country>Россия</country></aff><aff xml:lang="en">State Research Center of Virology and Biotechnology ”Vector”&#13;
&#13;
Institute of Cytology and Genetics SB RAS<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>03</day><month>02</month><year>2017</year></pub-date><volume>20</volume><issue>6</issue><fpage>949</fpage><lpage>953</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Максютов Р.А., Колосова И.В., Трегубчак Т.В., Разумов И.А., Щелкунов С.Н., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Максютов Р.А., Колосова И.В., Трегубчак Т.В., Разумов И.А., Щелкунов С.Н.</copyright-holder><copyright-holder xml:lang="en">Maksyutov R.A., Kolosova I.V., Tregubchak T.V., Razumov I.A., Shchelkunov S.N.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vavilov.elpub.ru/jour/article/view/876">https://vavilov.elpub.ru/jour/article/view/876</self-uri><abstract><p>В современном мире одно из активно развивающихся направлений в лечении онкологических заболеваний – виротерапия, особенностью которой является избирательное уничтожение раковых клеток при минимальном воздействии на здоровые клетки организма. Перспективной основой для создания онколитических препаратов могут стать ортопоксвирусы, имеющие ряд преимуществ перед другими вирусными векторами, одно из которых – большая емкость генома, что позволяет встраивать в их геном гены, кодирующие белки с различными противоопухолевыми свойствами. В данной работе проведено сравнительное изучение репликативных свойств десяти различных вариантов штамма ЛИВП вируса осповакцины (ВОВ), в которых встроены дополнительные гены гранулоцитарно-макрофагального колониестимулирующего фактора, апоптоз-индуцирующего белка TRAIL и гена зеленого флуоресцирующего белка, на перевиваемой культуре клеток глиобластомы человека U87 и почки африканской зеленой мартышки CV-1. Кроме того, изучен вирус с пятью удаленными генами вирулентности (гемагглютинина, γ-интер-ферон-связывающего белка, тимидинкиназы, комплемент- связывающего белка и Bcl-2-подобного ингибитора апоптоза), характеризующийся значительно меньшей реактогенностью и нейровирулентностью по сравнению с исходным штаммом ЛИВП ВОВ. Полученные данные свидетельствуют о том, что в культуре клеток глиобластомы активнее всего реплицируются различные варианты ВОВ с нарушенным геном тимидинкиназы.</p></abstract><trans-abstract xml:lang="en"><p>In the world of today, virotherapy is one of the rapidly developing areas in the treatment of cancer, and its advantage is selective destruction of cancer cells with minimizing the destructive effect on normal cells of the body. A promising basis for the creation of oncolytic drugs is orthopoxviruses, which have a number of advantages over other viral vectors, and one of these advantages is a large capacity of the genome, which allows genes encoding proteins with antitumor properties to be cloned into their genome. In this study, we compared the replicative properties of ten variants of vaccinia virus (the strain LIVP of VACV) using human glioblastoma cell culture; some of these viruses have additional genes, such as the gene encoding granulocyte-macrophage colony stimulating factor, gene encoding apoptosis-inducing protein TRAIL and gene encoding green fluorescent protein. Furthermore, the virus with five virulence genes deleted (genes encoding hemagglutinin, γ-interferonbinding protein, thymidine kinase, complementbinding protein and Bcl2-like inhibitor of apoptosis), which has significantly lower reactogenicity and neurovirulence compared to the original strain LIVP of VACV, was studied. These data suggest that variants of vaccinia virus with a defective gene encoding thymidine kinase most actively replicate in glioblastoma cell culture.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>культура клеток глиобластомы</kwd><kwd>виротерапия</kwd><kwd>онколитический вирус</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glioblastoma cell culture</kwd><kwd>virotherapy</kwd><kwd>oncolytic virus</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bienkowska-Szewczyk K., Szewczyk B. Expression of genes coding for viral glycoproteins in heterologous systems. Acta Biochim. Pol. 1999;2:325-339.</mixed-citation><mixed-citation xml:lang="en">Bienkowska-Szewczyk K., Szewczyk B. Expression of genes coding for viral glycoproteins in heterologous systems. Acta Biochim. Pol. 1999;2:325-339.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chiocca E.A., Aguilar L.K., Bell S.D., Kaur B., Hardcastle J., Cavaliere R., McGregor J., Lo S., Ray-Chaudhuri A., Chakravarti A., Grecula J., Newton H., Harris K.S., Grossman R.G., Trask T.W., Baskin D.S., Monterroso C., Manzanera A.G., Aguilar-Cordova E., New P.Z. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncol. 2011;29(27):3611-3619. DOI 10.1200/JCO.2011.35.5222.</mixed-citation><mixed-citation xml:lang="en">Chiocca E.A., Aguilar L.K., Bell S.D., Kaur B., Hardcastle J., Cavaliere R., McGregor J., Lo S., Ray-Chaudhuri A., Chakravarti A., Grecula J., Newton H., Harris K.S., Grossman R.G., Trask T.W., Baskin D.S., Monterroso C., Manzanera A.G., Aguilar-Cordova E., New P.Z. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncol. 2011;29(27):3611-3619. DOI 10.1200/JCO.2011.35.5222.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ding Z.Y., Wei Y.Q. Cancer biotherapy: Progress in China. Recent Advances Cancer Res. Ther. 2012:1-31. DOI 10.1016/B978-0-12-397833-2.00001-7.</mixed-citation><mixed-citation xml:lang="en">Ding Z.Y., Wei Y.Q. Cancer biotherapy: Progress in China. Recent Advances Cancer Res. Ther. 2012:1-31. DOI 10.1016/B978-0-12-397833-2.00001-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Doniņa S., Strēle I., Proboka G., Auziņš J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421-426. DOI 10.1097/CMR.0000000000000180.</mixed-citation><mixed-citation xml:lang="en">Doniņa S., Strēle I., Proboka G., Auziņš J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421-426. DOI 10.1097/CMR.0000000000000180.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hulou M.M., Cho C.F., Chiocca E.A., Bjerkvig R. Experimental therapies: gene therapies and oncolytic viruses. Handb. Clin. Neurol. 2016;134:183-197. DOI 10.1016/B978-0-12-802997- 8.00011-6.</mixed-citation><mixed-citation xml:lang="en">Hulou M.M., Cho C.F., Chiocca E.A., Bjerkvig R. Experimental therapies: gene therapies and oncolytic viruses. Handb. Clin. Neurol. 2016;134:183-197. DOI 10.1016/B978-0-12-802997- 8.00011-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jackson C., Westphal M., Quiñones-Hinojosa A. Complications of glioma surgery. Handb. Clin. Neurol. 2016;134:201-218. DOI 10.1016/B978-0-12-802997-8.00012-8.</mixed-citation><mixed-citation xml:lang="en">Jackson C., Westphal M., Quiñones-Hinojosa A. Complications of glioma surgery. Handb. Clin. Neurol. 2016;134:201-218. DOI 10.1016/B978-0-12-802997-8.00012-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karim R., Palazzo C., Evrard B., Piel G. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. J. Control. Release. 2016;227:23-37. DOI 10.1016/j.jconrel.2016.02.026.</mixed-citation><mixed-citation xml:lang="en">Karim R., Palazzo C., Evrard B., Piel G. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. J. Control. Release. 2016;227:23-37. DOI 10.1016/j.jconrel.2016.02.026.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Liang M. Clinical development of oncolytic viruses in China. Curr. Pharm. Biotechnol. 2012;13(9):1852-1857.</mixed-citation><mixed-citation xml:lang="en">Liang M. Clinical development of oncolytic viruses in China. Curr. Pharm. Biotechnol. 2012;13(9):1852-1857.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. DOI 10.1007/s00401-007-0243-4.</mixed-citation><mixed-citation xml:lang="en">Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. DOI 10.1007/s00401-007-0243-4.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maksyutov R.A., Tregubchak T.V., Denisova N.I., Maksyutov A.Z., Gavrilova E.V. Creating a modern platform comprising a set of oncolytic viruses with immune-stimulating properties. Rossiyskiy immunologicheskiy zhurnal = Russian Immunological Journal. 2013; 7(4):456-459. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Maksyutov R.A., Tregubchak T.V., Denisova N.I., Maksyutov A.Z., Gavrilova E.V. Creating a modern platform comprising a set of oncolytic viruses with immune-stimulating properties. Rossiyskiy immunologicheskiy zhurnal = Russian Immunological Journal. 2013; 7(4):456-459. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46(10):5276-5281.</mixed-citation><mixed-citation xml:lang="en">Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46(10):5276-5281.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Perry A., Wesseling P. Histologic classification of gliomas. Handb. Clin. Neurol. 2016;134:71- 95. DOI 10.1016/B978-0-12-802997-8.00005-0.</mixed-citation><mixed-citation xml:lang="en">Perry A., Wesseling P. Histologic classification of gliomas. Handb. Clin. Neurol. 2016;134:71- 95. DOI 10.1016/B978-0-12-802997-8.00005-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Petrov I.S., Goncharova E.P., Kolosovа I.V., Pozdnyakov S.G., Schelkunov S.N., Zenkova M.A., Vlasov V.V. Antitumor effect of the LIVP-GFP recombinant vaccinia virus. Doklady Akademii nauk = Reports of the Academy of Sciences. 2013;451(5):592-597. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Petrov I.S., Goncharova E.P., Kolosovа I.V., Pozdnyakov S.G., Schelkunov S.N., Zenkova M.A., Vlasov V.V. Antitumor effect of the LIVP-GFP recombinant vaccinia virus. Doklady Akademii nauk = Reports of the Academy of Sciences. 2013;451(5):592-597. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pol J., Kroemer G., Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunol. 2015;5(1):e1115641. DOI 10.1080/2162402X.2015.1115641.</mixed-citation><mixed-citation xml:lang="en">Pol J., Kroemer G., Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunol. 2015;5(1):e1115641. DOI 10.1080/2162402X.2015.1115641.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Snider J.W., Mehta M. Principles of radiation therapy. Handb. Clin. Neurol. 2016;134:131-147. DOI 10.1016/B978-0-12-802997-8.00008-6.</mixed-citation><mixed-citation xml:lang="en">Snider J.W., Mehta M. Principles of radiation therapy. Handb. Clin. Neurol. 2016;134:131-147. DOI 10.1016/B978-0-12-802997-8.00008-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987- 996.</mixed-citation><mixed-citation xml:lang="en">Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987- 996.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Urazova L.N., Kuznetsova T.I. Oncolytic viruses in oncology. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology. 2013;4: 28-35. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Urazova L.N., Kuznetsova T.I. Oncolytic viruses in oncology. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology. 2013;4: 28-35. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Weibel S., Raab V., Yu Y.A., Worschech A., Wang E., Marincola F.M., Szalay A.A. Viral- mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer. 2011;11:68. DOI 10.1186/1471-2407-11-68.</mixed-citation><mixed-citation xml:lang="en">Weibel S., Raab V., Yu Y.A., Worschech A., Wang E., Marincola F.M., Szalay A.A. Viral- mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer. 2011;11:68. DOI 10.1186/1471-2407-11-68.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Westphal M., Ylä-Herttuala S., Martin J., Warnke P., Menei P., Eckland D., Kinley J., Kay R., Ram Z.; ASPECT Study Group. Adenovirus- mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(9):823-833. DOI 10.1016/S1470-2045(13)70274-2.</mixed-citation><mixed-citation xml:lang="en">Westphal M., Ylä-Herttuala S., Martin J., Warnke P., Menei P., Eckland D., Kinley J., Kay R., Ram Z.; ASPECT Study Group. Adenovirus- mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(9):823-833. DOI 10.1016/S1470-2045(13)70274-2.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yakubitskyi S.N., Kolosova I.V., Maksyutov R.A., Shchelkunov S.N. Attenuation of vaccinia virus. Acta Naturae. 2015;7:108-117. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Yakubitskyi S.N., Kolosova I.V., Maksyutov R.A., Shchelkunov S.N. Attenuation of vaccinia virus. Acta Naturae. 2015;7:108-117. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zav’yalov E.L., Razumov I.A., Gerlinskaya L.A., Romashchenko A.V. In vivo MRI visualization of growth and morphology in the orthotopic xenotransplantation U87 glioblastoma mouse SCID model. Vavilovskii Zhurnal Genetiki i Selektsii = Vavilov Journal of Genetics and Breeding. 2015;19(4):460-465. DOI 10.18699/VJ15.061. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Zav’yalov E.L., Razumov I.A., Gerlinskaya L.A., Romashchenko A.V. In vivo MRI visualization of growth and morphology in the orthotopic xenotransplantation U87 glioblastoma mouse SCID model. Vavilovskii Zhurnal Genetiki i Selektsii = Vavilov Journal of Genetics and Breeding. 2015;19(4):460-465. DOI 10.18699/VJ15.061. (in Russian)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
